Q4 2025 EPS Estimates for Thermo Fisher Scientific Inc. Increased by Zacks Research (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities researchers at Zacks Research increased their Q4 2025 earnings estimates for shares of Thermo Fisher Scientific in a research report issued on Wednesday, August 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.90 per share for the quarter, up from their previous estimate of $5.30. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.72 per share.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. The business’s quarterly revenue was down 1.4% compared to the same quarter last year.

TMO has been the subject of a number of other research reports. HSBC boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. TD Cowen raised their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Barclays reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Raymond James raised their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Trading Up 1.1 %

NYSE:TMO opened at $614.54 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The company’s 50 day moving average is $572.16 and its 200-day moving average is $572.87. The firm has a market cap of $234.75 billion, a price-to-earnings ratio of 39.42, a P/E/G ratio of 2.81 and a beta of 0.77. Thermo Fisher Scientific has a 12 month low of $415.60 and a 12 month high of $622.30.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,084 shares of company stock valued at $19,767,092. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC raised its stake in shares of Thermo Fisher Scientific by 17.0% during the fourth quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock worth $1,010,000 after buying an additional 276 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $107,000. J.W. Cole Advisors Inc. grew its stake in shares of Thermo Fisher Scientific by 33.2% during the fourth quarter. J.W. Cole Advisors Inc. now owns 2,242 shares of the medical research company’s stock worth $1,190,000 after purchasing an additional 559 shares during the period. Verdence Capital Advisors LLC lifted its stake in Thermo Fisher Scientific by 1.5% in the fourth quarter. Verdence Capital Advisors LLC now owns 3,868 shares of the medical research company’s stock valued at $2,053,000 after buying an additional 58 shares during the period. Finally, First Command Advisory Services Inc. boosted its holdings in Thermo Fisher Scientific by 15.4% during the fourth quarter. First Command Advisory Services Inc. now owns 689 shares of the medical research company’s stock worth $366,000 after buying an additional 92 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.